BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, ...
BioNexus Gene Lab Corp. (BGLC) is a life-science and industrial-distribution company headquartered in Kuala Lumpur, Malaysia, with operations organized around two main business lines through its subsidiaries. The company’s Chemrex Corporation Sdn. Bhd. focuses on wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other Southeast Asian ...BioNexus Gene Lab Corp. (BGLC) is a life-science and industrial-distribution company headquartered in Kuala Lumpur, Malaysia, with operations organized around two main business lines through its subsidiaries. The company’s Chemrex Corporation Sdn. Bhd. focuses on wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other Southeast Asian markets. The supplied chemical inputs are used in manufacturing a range of downstream products, including handrails, bench tops, components for automotive and aerospace applications, cleanroom panels, and various instruments. This distribution segment functions as an industrial supply channel and typically ties revenue to sourcing, inventory management, and customer demand across multiple end markets.
In parallel, BioNexus Gene Lab Sdn. Bhd. represents the company’s biotechnology/diagnostics activity. BGLC develops and provides non-invasive liquid biopsy tests designed for earlier detection of biomarkers. The company’s approach is described as blood-based, dynamic genome/RNA-based screening that analyzes changes in ribonucleic acid (RNA). From a product perspective, the core offering is diagnostic testing rather than a traditional pharmaceutical product, and its value proposition is linked to clinical utility, speed, and the ability to detect biomarker signals without invasive sampling.
Leadership is currently associated with CEO Su-Leng Tan (CEO/Director role noted as of December 11, 2023). The company was incorporated in 2017 and is listed on the NASDAQ Capital Market under the ticker BGLC.
In terms of operating scale, the company reports relatively small headcount (full-time employees shown as 27 in the provided dataset), which is consistent with an early-stage/lean organization supporting both distribution operations and R&D/diagnostics development. Financial metrics in the provided snapshot show weak profitability on a trailing-twelve-month basis (negative margins and negative return measures such as return on assets/equity), suggesting the business may be in a development and build-out phase for its diagnostics activities and/or experiencing margin pressure. Liquidity indicators in the dataset include relatively strong current ratio and quick ratio measures, which can be consistent with the ability to fund working capital needs—particularly important for both distribution (inventory and receivables) and for sustaining test-development and commercialization efforts.
Overall, BGLC’s business strategy combines an industrial distribution stream that can support operations with a diagnostics stream aiming to establish non-invasive testing capabilities for biomarker-based early detection. Future success would likely depend on expanding test adoption and validating clinical performance while maintaining reliable chemical supply/customer relationships and controlling costs (including R&D and general & administrative expenses).
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$7.4M
-21.9%
+233.4%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-3.0M
-86.7%
+47.3%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+14.6%
+7.8%
+117.1%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-42.5%
-157.1%
+85.2%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-40.2%
-139.2%
+84.2%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-1.9M
+23.8%
-199.8%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-25.3%
+2.4%
+10.1%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
2.0%
-19.2%
-4.5%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
10.46x
+174.7%
-6.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
